{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:03:19Z","timestamp":1784818999411,"version":"3.55.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:p>Vulvar and vaginal melanomas (VVMs) are rare malignancies, but they are relatively more common among Asian women. This makes the collection of data on VVMs in this population crucial. Moreover, no cohort studies have examined and compared the effects of immune checkpoint inhibitors (ICIs) on VVM in Asian women. Therefore, we aimed to investigate the clinical characteristics of VVMs in Japanese women and the effects of ICI treatment. This single-center, retrospective cohort study included patients who were histologically diagnosed with VVM at our hospital between March 2005 and December 2023. The Kaplan\u2013Meier analysis was used to compare the prognosis of vulvar melanoma (VuM) and vaginal melanoma (VaM) throughout entire treatments and compare the efficacies of ICIs and conventional chemotherapies in VVM. In total, 28 women with VuM (<jats:italic toggle=\"yes\">n<\/jats:italic>\u2005=\u200514) and VaM (<jats:italic toggle=\"yes\">n<\/jats:italic>\u2005=\u200514) were included. There were no significant differences in overall survival (OS) [median OS: not reached (95% confidence interval (CI), 13.2\u2013NA) vs. 30.2 months (95% CI, 23.2\u2013NA), log-rank test, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u20050.456] between the VuM and VaM groups. The progression-free survival (median progression-free survival: 14.7 vs. 5.2 months, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u20050.002) and OS (median OS: 33.8 vs. 7.2 months, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u20050.001) were significantly better for the ICI-treated group than for the conventional chemotherapy-treated group in VVM. The prognosis of patients with VVM improved significantly with the advent of ICI, demonstrating the importance of ICI in the treatment of VVM.<\/jats:p>","DOI":"10.1097\/cmr.0000000000001012","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T19:00:15Z","timestamp":1733338815000},"page":"67-74","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Clinical features of vulvar and vaginal malignant melanomas and the effects of immune checkpoint inhibitors in Japanese patients: a single-center, retrospective cohort study"],"prefix":"10.1097","volume":"35","author":[{"given":"Ken","family":"Horisaki","sequence":"first","affiliation":[{"name":"Department of Dermatology, Shizuoka Cancer Center, Shizuoka, Japan"},{"name":"Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusuke","family":"Yoshikawa","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Shizuoka Cancer Center, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Omata","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Shizuoka Cancer Center, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arata","family":"Tsutsumida","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Shizuoka Cancer Center, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Kiyohara","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Shizuoka Cancer Center, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,12,3]]},"reference":[{"key":"R1-20250109","first-page":"1005","article-title":"Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification.","volume":"28","author":"Rastrelli","year":"2014","journal-title":"In Vivo"},{"key":"R2-20250109","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1002\/ijc.28625","article-title":"Epidemiology and survival outcomes of ocular and mucosal melanomas: a population-based analysis.","volume":"134","author":"Bishop","year":"2014","journal-title":"Int J Cancer"},{"key":"R3-20250109","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jaad.2016.08.007","article-title":"Mucosal melanomas in the racially diverse population of California.","volume":"76","author":"Altieri","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"R4-20250109","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1245\/s10434-018-6503-9","article-title":"Multifactorial analysis of prognostic factors and survival rates among 706 mucosal melanoma patients.","volume":"25","author":"Cui","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"R5-20250109","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11912-018-0675-0","article-title":"Mucosal melanoma: a literature review.","volume":"20","author":"Yde","year":"2018","journal-title":"Curr Oncol Rep"},{"key":"R7-20250109","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/01.AOG.0000271209.67461.91","article-title":"Vulvar melanoma: a multivariable analysis of 644 patients.","volume":"110","author":"Sugiyama","year":"2007","journal-title":"Obstet Gynecol"},{"key":"R8-20250109","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3892\/mco.2017.1158","article-title":"A retrospective clinical analysis of 5 cases of vaginal melanoma.","volume":"6","author":"Tasaka","year":"2017","journal-title":"Mol Clin Oncol"},{"key":"R9-20250109","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3322\/canjclin.49.1.8","article-title":"Cancer statistics, 1999.","volume":"49","author":"Landis","year":"1999","journal-title":"CA Cancer J Clin"},{"key":"R10-20250109","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.annonc.2022.06.004","article-title":"Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study.","volume":"33","author":"Dimitriou","year":"2022","journal-title":"Ann Oncol"},{"key":"R11-20250109","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jdcr.2023.05.037","article-title":"Long-term response of vulvar mucosal melanoma treated with neoadjuvant nivolumab.","volume":"38","author":"Dubus","year":"2023","journal-title":"JAAD Case Rep"},{"key":"R12-20250109","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1111\/jdv.14486","article-title":"Are checkpoint inhibitors a valuable option for metastatic or unresectable vulvar and vaginal melanomas?","volume":"32","author":"Qu\u00e9reux","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R13-20250109","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/LGT.0000000000000583","article-title":"Clinical characteristics and treatment response with checkpoint inhibitors in malignant melanoma of the vulva and vagina.","volume":"25","author":"Wohlmuth","year":"2021","journal-title":"J Low Genit Tract Dis"},{"key":"R14-20250109","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00795-023-00377-6","article-title":"Usage of nivolumab and ipilimumab for recurrent or advanced malignant vaginal melanoma: a two-case series.","volume":"57","author":"Konishi","year":"2024","journal-title":"Med Mol Morphol"},{"key":"R15-20250109","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/CMR.0000000000000894","article-title":"Clinicopathological demographics of malignant melanomas of the vulva and vagina in Japan.","volume":"33","author":"Ogata","year":"2023","journal-title":"Melanoma Res"},{"key":"R16-20250109","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40257-019-00487-x","article-title":"Malignant melanoma of the vulva and vagina: a US population-based study of 1863 patients.","volume":"21","author":"Wohlmuth","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"R17-20250109","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/CMR.0000000000000480","article-title":"Female genitourinary tract melanoma: mutation analysis with clinicopathologic correlation: a single-institution experience.","volume":"28","author":"Saglam","year":"2018","journal-title":"Melanoma Res"},{"key":"R18-20250109","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/0090-8258(92)90300-8","article-title":"Management of vulvar melanoma.","volume":"45","author":"Trimble","year":"1992","journal-title":"Gynecol Oncol"},{"key":"R19-20250109","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/ijgc-00009577-200109000-00004","article-title":"Vulvar melanoma at the M. D. Anderson Cancer Center: 25 years later.","volume":"11","author":"Verschraegen","year":"2001","journal-title":"Int J Gynecol Cancer"},{"key":"R20-20250109","first-page":"220","article-title":"Management of vulvar melanoma and review of the literature.","volume":"28","author":"Suwandinata","year":"2007","journal-title":"Eur J Gynaecol Oncol"},{"key":"R21-20250109","doi-asserted-by":"crossref","first-page":"115","DOI":"10.11604\/pamj.2021.38.115.25864","article-title":"Malignant nodular melanoma of the vulva: a rare and aggressive tumour of the female genital tract (case report).","volume":"38","author":"Khaba","year":"2021","journal-title":"Pan Afr Med J"},{"key":"R22-20250109","doi-asserted-by":"crossref","first-page":"MMT66","DOI":"10.2217\/mmt-2023-0001","article-title":"Organ-sparing central pelvic compartment resection for the treatment of vulvo-vaginal melanomas.","volume":"10","author":"McGowan","year":"2024","journal-title":"Melanoma Manag"},{"key":"R23-20250109","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.4103\/jcrt.JCRT_893_15","article-title":"Primary vaginal malignant melanoma: a rare entity with review of literature.","volume":"15","author":"Puri","year":"2019","journal-title":"J Cancer Res Ther"},{"key":"R24-20250109","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/LGT.0000000000000142","article-title":"Malignant melanoma of vulva and vagina: a histomorphological review and mutation analysis--A single-center study.","volume":"19","author":"Rouzbahman","year":"2015","journal-title":"J Low Genit Tract Dis"},{"key":"R25-20250109","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11864-019-0607-8","article-title":"Targeted therapy and immunotherapy for melanoma in Japan.","volume":"20","author":"Namikawa","year":"2019","journal-title":"Curr Treat Options Oncol"},{"key":"R26-20250109","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1001\/jama.2011.746","article-title":"KIT as a therapeutic target in metastatic melanoma.","volume":"305","author":"Carvajal","year":"2011","journal-title":"JAMA"},{"key":"R27-20250109","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1200\/JCO.2010.33.9275","article-title":"Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.","volume":"29","author":"Guo","year":"2011","journal-title":"J Clin Oncol"},{"key":"R28-20250109","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1200\/JCO.2012.47.7836","article-title":"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.","volume":"31","author":"Hodi","year":"2013","journal-title":"J Clin Oncol"},{"key":"R29-20250109","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ygyno.2013.02.028","article-title":"Vulvar and vaginal melanoma: Case series and review of current management options including neoadjuvant chemotherapy.","volume":"129","author":"Janco","year":"2013","journal-title":"Gynecologic Oncol"}],"container-title":["Melanoma Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CMR.0000000000001012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T22:07:01Z","timestamp":1736460421000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CMR.0000000000001012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,3]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/cmr.0000000000001012","relation":{},"ISSN":["0960-8931","1473-5636"],"issn-type":[{"value":"0960-8931","type":"print"},{"value":"1473-5636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,3]]}}}